AdarX Pharmaceuticals Inc., a late-stage gene therapy research and development company, officially announced an increase in the initial public offering price and successfully raised US$446.3 million. The sale was ultimately priced at the top of its original market-guidance range of $15 to $17 — or $17 per share.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.